ArticleBritish journal of cancer1998
Prostate-specific antigen and gross cystic disease fluid protein-15 are co-expressed in androgen receptor-positive breast tumours.
Article in British journal of cancer, 1998. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 53 citations in OpenAlex.
- Gross cystic disease fluid protein 15 (GCDFP-15) expression in breast cancer subtypes.BMC cancer · 2014Trial
- Beyond Prostate Cancer: An Androgen Receptor Splice Variant Expression in Multiple Malignancies, Non-Cancer Pathologies, and Development.Biomedicines · 2023Review
- Immunoexpression of the GCDFP-15 Marker in Different Grades of Breast Carcinoma.Iranian journal of pathology · 2023Article
- Reconnoitring the status of prostate specific antigen and its role in women.Indian journal of clinical biochemistry : IJCB · 2015Review
- Minireview: The androgen receptor in breast tissues: growth inhibitor, tumor suppressor, oncogene?Molecular endocrinology (Baltimore, Md.) · 2012Review
- Runx2 controls a feed-forward loop between androgen and prolactin-induced protein (PIP) in stimulating T47D cell proliferation.Journal of cellular physiology · 2012Article
- The expression of prostate-specific antigen in invasive breast carcinoma and its relationship with routine clinicopathologic parameters.Advanced biomedical research · 2012Article
- Diagnostic value of prostate-specific antigen in women with polycystic ovary syndrome.Journal of research in medical sciences : the official journal of Isfahan University of Medical Sciences · 2011Article
- Prostate-specific antigen and hormone receptor expression in male and female breast carcinoma.Diagnostic pathology · 2010Article
- Reciprocal regulation of ZEB1 and AR in triple negative breast cancer cells.Breast cancer research and treatment · 2010Article
- Expression of aberrant mucins in lobular carcinoma with histiocytoid feature of the breast.Virchows Archiv : an international journal of pathology · 2007Article
- Expression of the prolactin-inducible protein (PIP/GCDFP15) gene in benign epithelium and adenocarcinoma of the prostate.Cancer science · 2004Article
- Expression of androgen receptor and prostate-specific antigen in male breast carcinoma.Breast cancer research : BCR · 2004Article
- Codon 89 polymorphism in the human 5 alpha-reductase gene in primary breast cancer.British journal of cancer · 2001Article
- The potential role for prolactin-inducible protein (PIP) as a marker of human breast cancer micrometastasis.British journal of cancer · 1999Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Androgens regulate breast cancer cell proliferation via androgen receptor (AR)-mediated mechanisms. To investigate further the androgen-responsiveness of human breast tumours, we examined the immunohistochemical expression of the AR and two androgen-regulated proteins, prostate-specific antigen (PSA) and gross cystic disease fluid protein-15 (GCDFP-15), in 72 primary breast tumours. AR immunoreactivity was present in the nuclei of breast tumour cells and was correlated with oestrogen receptor (ER; P < 0.05) and progesterone receptor (PR; P < 0.01) status. PSA and GCDFP-15 immunoreactivity was present in the cytoplasm of tumour cells but not the adjacent stromal cells. AR-positive cells were present in 85% (61/72) of breast tumours, and 98% (43/44) of PSA-positive and 92% (44/48) of GCDFP-15-positive tumours were also positive for AR. Positive immunoreactivity for both PSA and GCDFP-15 in breast tumours was highly dependent on AR status (odds ratios of 24.0 and 4.5 respectively), but unrelated to age, ER and PR status and axillary lymph node involvement. PSA immunoreactivity was more frequently observed in moderate and well-differentiated tumours and was significantly (P < 0.001) associated with GCDFP-15 immunoreactivity. In conclusion, PSA and GCDFP-15 immunoreactivity was dependent on the presence of AR, but not ER or PR in primary breast tumours.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.